Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

L.A. McKeown

May 22, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2021

Caitlin E. Cox

May 03, 2021

News Daily News

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Shelley Wood

April 09, 2021

News Conference News AHA 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Michael O'Riordan

November 14, 2020

News Daily News

Superiority of Ticagrelor Over Clopidogrel in ACS Questioned

Todd Neale

October 29, 2020

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

Caitlin E. Cox

August 06, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

News Conference News ACC 2019

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Shelley Wood

March 19, 2019

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Shelley Wood

September 14, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

Advertisement

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Top Coronary Artery Disease News of 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

TCTMD’s Top 10 Most Popular Stories for April 2021

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Superiority of Ticagrelor Over Clopidogrel in ACS Questioned

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TAVR Bleeds Stand Apart From PCI-Related Events

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content